- Home
- OSPN vs REPL Comparison
OSPN vs REPL Comparison
Compare OSPN & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSPN
- REPL
- Stock Information
- Founded
- OSPN 1991
- REPL 2015
- Country
- OSPN United States
- REPL United States
- Employees
- OSPN N/A
- REPL N/A
- Industry
- OSPN EDP Services
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- OSPN Technology
- REPL Health Care
- Exchange
- OSPN Nasdaq
- REPL Nasdaq
- Market Cap
- OSPN 597.9M
- REPL 547.0M
- IPO Year
- OSPN 1998
- REPL 2018
- Fundamental
- Price
- OSPN $15.79
- REPL $5.71
- Analyst Decision
- OSPN Strong Buy
- REPL Hold
- Analyst Count
- OSPN 3
- REPL 9
- Target Price
- OSPN $19.67
- REPL $7.00
- AVG Volume (30 Days)
- OSPN 447.2K
- REPL 2.1M
- Earning Date
- OSPN 10-29-2025
- REPL 11-11-2025
- Dividend Yield
- OSPN 3.07%
- REPL N/A
- EPS Growth
- OSPN 265.73
- REPL N/A
- EPS
- OSPN 1.53
- REPL N/A
- Revenue
- OSPN $240,621,000.00
- REPL N/A
- Revenue This Year
- OSPN $4.23
- REPL N/A
- Revenue Next Year
- OSPN $5.58
- REPL $408.25
- P/E Ratio
- OSPN $10.22
- REPL N/A
- Revenue Growth
- OSPN N/A
- REPL N/A
- 52 Week Low
- OSPN $12.51
- REPL $2.68
- 52 Week High
- OSPN $20.37
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- OSPN 63.37
- REPL 46.92
- Support Level
- OSPN $15.27
- REPL $5.60
- Resistance Level
- OSPN $15.79
- REPL $6.15
- Average True Range (ATR)
- OSPN 0.35
- REPL 0.33
- MACD
- OSPN 0.09
- REPL 0.06
- Stochastic Oscillator
- OSPN 81.65
- REPL 32.48
About OSPN OneSpan Inc.
OneSpan Inc is a provider of information technology security solutions for banking and financial services and application security markets. Its solutions secure and manage access to digital assets and protect online transactions, via mobile devices and in-person. Authentication and anti-fraud solutions are the organization's primary product offerings and include multifactor authentication and virtual private network access capabilities. The company derives revenues from hardware and license fees, maintenance and support fees, and subscription fees. A large majority of the firm's revenue is generated in Europe, the Middle East, and Africa, and the rest in the United States and Asia-Pacific region.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.